Labcorp stock (LH): Q1 earnings beat with $4.25 EPS

Labcorp reported Q1 2026 earnings on April 30, beating estimates with $4.25 EPS and 5.8% revenue growth to $3.54 billion. Shares trade at $257.13 on NYSE.

Labcorp Holdings (NYSE: LH) released its Q1 2026 earnings on April 30, 2026, posting adjusted EPS of $4.25, surpassing analyst consensus of $4.09 by $0.16. Quarterly revenue increased 5.8% year-over-year to $3.54 billion, topping estimates of $3.51 billion, according to MarketBeat as of 05/12/2026. The stock closed at $257.13 on May 12, 2026, up 0.81% that day on NYSE.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Laboratory Corporation of America Holdings
• Sector/industry: Healthcare / Diagnostics & Laboratory Services
• Headquarters/country: United States
• Core markets: North America, global life sciences
• Key revenue drivers: Clinical lab testing, drug development
• Home exchange/listing venue: NYSE (LH)
• Trading currency: USD

Labcorp: core business model

Laboratory Corporation of America Holdings, known as Labcorp (NYSE: LH), operates as a global life sciences leader offering clinical laboratory services and drug development solutions. The company processes millions of diagnostic tests annually, supporting healthcare providers and biopharma firms. Its diagnostics segment generates the bulk of revenue through routine and specialty lab testing, according to company filings cited on MarketBeat as of 05/12/2026.

Labcorp's drug development business provides end-to-end services from early-phase trials to commercialization, serving over 100 countries. This dual focus positions it as a key player in personalized medicine and precision diagnostics, with exposure to US healthcare spending trends relevant for American investors.

Main revenue and product drivers for Labcorp

Labcorp's primary revenue comes from its Diagnostics segment, which accounted for the majority of Q1 2026 sales at $3.54 billion total revenue. Key drivers include oncology, women's health, and infectious disease testing. The company benefits from steady demand in routine lab work amid an aging US population, per Q1 results published April 30, 2026, via MarketBeat as of 05/12/2026.

Drug development services contribute through central lab, Phase I-III trials, and companion diagnostics. Recent expansions, like partnerships with Epic systems, enhance data integration for lab orders, supporting growth as noted in Simply Wall St as of recent publication. Trailing 12-month EPS stands at $11.29 with a P/E of 22.50.

Conclusion

Labcorp's Q1 2026 results showed resilient growth with EPS and revenue beats, amid a stock up 1.4% year-to-date to around $254-257 levels on NYSE. Ongoing expansions in diagnostics and drug services underscore its role in US healthcare. Investors track upcoming quarters for sustained momentum in a competitive sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.